Catching the Next Wave: Airports as a Point of Traveler and Wastewater COVID Monitoring Networks

Introduction - Global Landscape of COVID-19 Pandemic

The global landscape of infectious disease monitoring has undergone a profound paradigm shift since the onset of the SARS-CoV-2 pandemic. Traditional case-based surveillance, while foundational to public health and epidemiology, is inherently reactive and subject to significant temporal lags. It relies on a cascade of dependent events: an individual must become infected, complete an incubation period, develop recognizable clinical symptoms, seek medical care, and undergo specific diagnostic testing. Only after this chain of events is data reported to public health authorities. This structural delay often results in a massive gap between the initial introduction of a novel pathogen into a community and its formal detection, by which time widespread community transmission has typically already occurred. To bridge this critical temporal gap, genomic biosurveillance at international borders has emerged as a highly sophisticated early warning system. By intercepting viral pathogens at major transportation and transit chokepoints, public health infrastructure can detect emerging variants days or even weeks before they precipitate surges in local hospital admissions.

Airports serve as unique global mixing vessels, continuously aggregating highly mobile populations from diverse geographic regions and ecological zones. International travelers move rapidly across international boundaries, unwittingly carrying both endemic and emerging pathogens from their points of origin. Monitoring this specific demographic provides a concentrated, high-resolution window into the global circulation of communicable diseases. In response to the vulnerabilities exposed by the early pandemic, the United States Centers for Disease Control and Prevention initiated proactive pathogen tracking mechanisms designed to completely bypass the inherent delays of clinical reporting. This strategic framework leverages two primary modalities: the voluntary virological sampling of arriving passengers and the systematic analysis of aircraft wastewater. Together, these methods establish a comprehensive, multi-modal surveillance net capable of detecting novel biological threats. This report provides an exhaustive analysis of these border-based surveillance architectures, the mathematical and bioinformatic pipelines required to deconvolute complex environmental samples, and the intricate evolutionary dynamics of the novel SARS-CoV-2 variants currently being intercepted at international borders.

The Evolution of Border Biosurveillance Paradigms

The concept of border screening is not novel, but the integration of high-throughput genomic sequencing directly into airport operations represents a significant leap in biosecurity infrastructure. Historically, border interventions relied on syndromic screening, such as thermal scanners to detect fevers or visual inspections for signs of illness. These methods are notoriously ineffective for pathogens with high rates of asymptomatic or pre-symptomatic transmission, such as SARS-CoV-2. The shift toward genomic surveillance acknowledges that the molecular signature of a virus is a far more reliable indicator of its presence and potential threat level than the physical presentation of the host.

The Traveler-Based Genomic Surveillance program was conceptualized to address these specific shortfalls. By establishing voluntary testing stations directly within the arrival terminals of major international airports, public health officials created a frictionless mechanism for capturing viral samples from individuals who had just disembarked from high-risk or under-monitored regions. This approach not only identifies the presence of a virus but immediately subjects it to whole-genome sequencing to determine its exact lineage, variant, and mutational profile. The subsequent addition of environmental wastewater monitoring to this program created a complementary safety net, ensuring that even if participation in the voluntary human swabbing program fluctuated, the environmental shedding of the passenger cohort would still be captured and analyzed.

Architectural Framework of the Traveler-Based Genomic Surveillance Program

The Traveler-Based Genomic Surveillance program was officially launched by the Centers for Disease Control and Prevention in September 2021 as a targeted, localized pilot initiative.¹ The program's inception coincided with the global surge of the Delta variant, and initial efforts focused specifically on enrolling travelers arriving on direct flights from India at select United States airports.² Operating through strategic public-private partnerships with biotechnology and biosurveillance entities such as Ginkgo Bioworks and XpresCheck, the program quickly demonstrated its utility and has since been expanded into a permanent, highly sophisticated pillar of national biosecurity infrastructure.³

The operational model of the program is built around two distinct but complementary sample collection modalities. The first involves the collection of anonymous, voluntary nasal swabs provided by arriving international passengers. The second relies on the systematic and continuous collection of wastewater from arriving international aircraft.¹ The program has seen remarkable public acceptance; as of early 2026, the program surpassed a critical milestone of one million voluntary participants, marking a significant expansion of upstream pathogen surveillance.³

Initially designed as a single-pathogen monitoring system focused exclusively on SARS-CoV-2, the scope of the program was substantially broadened in late 2023. Leveraging advanced multiplexing technologies, the program now utilizes a custom multipathogen panel capable of simultaneously identifying more than thirty viral and bacterial targets.¹ This expanded panel includes critical respiratory pathogens such as Influenza A and B, Respiratory Syncytial Virus, and severe bacterial threats like Mycoplasma pneumoniae, effectively shifting the program from single-disease tracking to comprehensive syndromic and biothreat biomonitoring.¹

The physical footprint of the program has expanded in tandem with its diagnostic capabilities. Backed by doubled federal investment intended to substantially increase the volume of samples collected and sequenced, the network recently expanded to nine major active international airports in the United States.¹ The addition of facilities in Miami and Chicago augmented existing strategic sites located in Los Angeles, San Francisco, New York (JFK), Newark, Washington Dulles, Boston, and Seattle.¹ These locations were deliberately chosen for their high volumes of trans-oceanic flights and their status as primary entry nodes for travelers arriving from distinct global regions.

Program Feature	Pilot Phase (Late 2021)	Current Operations (2025-2026)
Pathogen Scope	SARS-CoV-2 exclusively	30+ targets (SARS-CoV-2, Influenza, RSV, Mycoplasma pneumoniae, etc.)
Participating Airports	4 to 7 initial hubs	9 major international hubs (including newly added Miami and Chicago)
Participant Volume	~16,000 early enrollees	Surpassed 1,000,000 total voluntary participants
Global Reach	Targeted origins (India, South Africa, UK)	Flights arriving from over 135 countries
Primary Output	Binary positive/negative and basic variant ID	High-throughput whole-genome sequencing and lineage deconvolution

Human Sampling Modalities and Laboratory Workflows

The human sampling component of the program relies on strategically placed mobile testing centers hosted directly within airport terminals. Arriving international passengers are invited to volunteer to self-collect nasal swab samples and complete a brief, anonymous survey regarding their travel history.¹ To maximize high-throughput screening efficiency and reduce laboratory backlogs, these individual samples were historically pooled. A pool typically combined swabs from five to twenty-five different travelers, organized based on their specific flight number or the country of flight origin.²

These pooled samples are shipped to dedicated laboratory networks and subjected to reverse transcription polymerase chain reaction testing to identify the presence of target pathogens.⁸ If a pooled sample returns a positive signal for a pathogen of public health concern, the laboratory protocol dictates that the individual samples comprising that pool are subsequently unsealed and re-tested individually.⁸ Any individual sample confirmed as positive then undergoes full genomic sequencing to determine the specific variant, strain, or novel mutation present.⁸ It is worth noting that as analytical capacities improved, the program adapted its data reporting structure; as of May 2025, the program shifted to focus more heavily on individual traveler data rather than aggregate pools, allowing for much more granular insights into the introduction of specific pathogens.⁵

Quantitative Efficacy and Early Warning Capabilities

The efficacy of this border-based approach is well-documented in the epidemiological literature. The program has repeatedly demonstrated its capacity to act as a highly sensitive early warning system, detecting novel variants with significant lead times before they are identified in domestic clinical settings.

During the initial pilot phase stretching from September 2021 through January 2022, the program enrolled approximately ten percent of eligible travelers on targeted flights, yielding a vast repository of sample pools.² Overall, sixteen percent of these pooled samples tested positive for SARS-CoV-2. The turnaround time from sample collection in the airport terminal to completed genomic sequencing averaged eleven business days, though this was expedited to under forty-eight hours for samples exhibiting S-gene target failures, a key early indicator for the Omicron variant.²

The positivity rates observed during this period starkly highlighted the varying regional burdens of the disease. While the overall positivity rate was low prior to late November 2021, it spiked to nearly twenty-one percent following the global emergence of Omicron. Positivity rates varied dramatically by the country of flight origin: pools arriving from South Africa exhibited a positivity rate of forty-three point five percent, pools from Brazil showed thirty-two point six percent, France twenty-five percent, the United Kingdom eighteen point four percent, and Germany seventeen point eight percent.²

Crucially, the genomic sequencing of these traveler samples allowed the United States to identify the early importation of critical variants. The program reported the very first domestic detection of the Omicron BA.2 sublineage a full seven days earlier than any other clinical or public health report in the country.² Similarly, the program detected the BA.3 sublineage in North America forty-three days before it was reported by any other surveillance network.² This early detection capability extends beyond SARS-CoV-2; the program has also successfully identified new influenza H3N2 subclades, submitting the genomic sequences to public databases several days before they were detected through traditional community surveillance or hospital admissions.³

This critical lead time provides immense practical value. For clinical and molecular laboratory leaders, early awareness of an emerging variant arriving at international borders informs immediate decisions regarding assay validation, test menu planning, the procurement of specific diagnostic reagents, and the adjustment of staffing levels prior to an anticipated surge in community transmission.³

Aircraft Wastewater Surveillance: Methodological Paradigms

While voluntary nasal swabbing provides high-resolution, individual-level genomic data directly linked to specific travel histories, it is inherently limited by traveler participation rates and self-selection biases. To overcome these limitations, the program incorporates the continuous monitoring of aircraft wastewater. Wastewater-based epidemiology relies on the biological reality that individuals infected with respiratory and gastrointestinal pathogens shed significant quantities of viral genetic material in their feces and urine.⁹ Crucially, this shedding often begins during the pre-symptomatic phase of infection and occurs robustly in entirely asymptomatic individuals, making it an unbiased indicator of population-level pathogen burdens.⁹

Aircraft wastewater presents a unique and highly advantageous matrix within the broader field of environmental surveillance. Traditional municipal wastewater is characterized by massive dilution. Viral RNA shed into a city sewer system is immediately mixed with vast quantities of greywater from showers and sinks, industrial chemical discharge, and occasionally stormwater runoff, significantly degrading the viral signal. In stark contrast, airplane lavatory waste is highly concentrated. Modern commercial aircraft utilize vacuum toilet systems that require minimal liquid flush volumes, resulting in a dense, undiluted suspension of biological material.¹¹

The program captures this environmental data through two distinct collection methods. The first involves direct extraction from individual airplanes using custom-designed collection devices that interface with the aircraft during routine servicing by lavatory trucks on the tarmac.⁸ This method represents a confined, well-defined epidemiological cohort—specifically, the passengers on a single long-haul flight. The second method involves aggregated collection from airport triturators using automated sampling devices.⁸ A triturator serves as a centralized consolidation point where multiple lavatory trucks deposit waste harvested from dozens of different flights.⁷ Because the triturator is isolated from the airport terminal's domestic waste system, the samples provide a pure aggregate representation of the international traveler population passing through the hub without dilution from local airport staff or domestic travelers.⁸

Viral Kinetics and Environmental Yields

Studies quantifying viral loads in aircraft wastewater demonstrate remarkably high concentrations, underscoring the efficiency of this surveillance modality. Research comparing samples taken directly from aircraft to those taken from domestic airport terminal wastewater systems found that the proportion of SARS-CoV-2-positive samples was significantly higher in the aircraft effluent.¹³ Specifically, between sixty and sixty-eight percent of aircraft wastewater samples tested positive for the virus, compared to only thirteen to forty-one percent of samples collected from the general airport terminal.¹³

The absolute viral concentrations recovered from aircraft are similarly profound. In quantitative assessments, viral concentrations from aircraft wastewater have been recorded ranging from hundreds of copies per milliliter to well over ten thousand copies per milliliter.¹² These exceptionally high viral loads provide a robust, clear signal for genomic sequencing, even when the overall prevalence of the disease in the community or on the flight is relatively low.¹² The sensitivity of this method is evident in its predictive capacity; specific variants of interest, such as various XBB sublineages, have been detected in aircraft wastewater from long-haul flights eighteen to thirty-one days prior to their appearance in local municipal water reclamation plants or in domestic clinical case reports.¹³

Matrix Type	Dilution Factor	Positivity Rate	Primary Surveillance Value
Municipal Wastewater	Very High (Mixed with greywater, industrial runoff)	Highly variable, dependent on community surges	Tracking broad community transmission trends over time.
Airport Terminal Wastewater	High (Mixed with local staff and domestic traveler waste)	13% to 41%	Monitoring general prevalence at a transit hub.
Aircraft Lavatory Wastewater	Very Low (Vacuum systems with minimal fluid)	60% to 68%	Intercepting novel variants from specific international origins before community entry.

RNA Extraction and Molecular Normalization

Extracting usable genomic material from raw wastewater requires rigorous laboratory protocols to overcome the presence of environmental inhibitors and physical degradation. A typical extraction methodology involves spinning down large volumes of influent wastewater in a centrifuge to separate the solid biological pellets from the liquid phase.⁹ These resulting pellets are then transferred to specialized bead tubes containing chemical lysis buffers designed to break open viral envelopes, inactivate the live virus, and chemically stabilize the fragile viral RNA.⁹ Following homogenization and phase separation, the total RNA is isolated, and its quantity and quality are measured using advanced spectrophotometry.⁹

To accurately track disease incidence trends and compare environmental data across different geographic locations, raw viral concentrations must be mathematically normalized. Raw viral counts in a sample can be heavily skewed by variations in total water usage, environmental degradation factors, and the total solid content of the specific sample.¹⁰ To resolve this ambiguity, researchers typically target specific SARS-CoV-2 nucleocapsid genes—most commonly designated as the N1 and N2 genes—using highly sensitive techniques like quantitative reverse transcription polymerase chain reaction or droplet digital polymerase chain reaction.⁹

For effective normalization, the concentration of these SARS-CoV-2 target genes in the settled solid phase of the wastewater is evaluated against a biological baseline. The most widely utilized baseline is the Pepper Mild Mottle Virus. This is a robust RNA virus that primarily infects agricultural pepper crops; because humans globally consume massive quantities of pepper products and sauces, the virus is excreted in human feces at exceptionally high, remarkably consistent concentrations regardless of geography.¹⁰ It therefore serves as a highly reliable endogenous indicator of total human fecal mass in a given sample.

The theoretical and mathematical modeling linking viral RNA in wastewater to actual community incidence relies on analyzing the ratio of the SARS-CoV-2 N gene to the Pepper Mild Mottle Virus. To calculate the concentration of viral RNA in the incoming wastewater, researchers conceptually model the virus as being introduced on a per-mass basis of feces, which is proportional to the total suspended solids in the water.¹⁰ The concentration of the virus is essentially a product of the solid fraction that is of fecal origin, multiplied by the proportion of the population actively shedding the virus, and the concentration of the virus within those feces. This product is then modified by an exponential decay function that accounts for the continuous degradation of the viral RNA during its transit from the human host to the eventual sampling location.¹⁰

Because both the SARS-CoV-2 RNA and the Pepper Mild Mottle Virus RNA undergo similar physical and chemical decay processes within the timeframe of collection within a sewer system, their respective decay rates effectively cancel each other out when expressed as a relative ratio.¹⁰ Consequently, researchers have established a reliable predictive model: a specific logarithmic increase in the ratio of the SARS-CoV-2 N gene to the Pepper Mild Mottle Virus is reliably associated with a proportional logarithmic increase in the incidence of laboratory-confirmed clinical cases within the contributing population.¹⁰ This mathematical normalization allows public health officials to look at raw sewage data and extrapolate highly accurate estimates of human disease burden.

Bioinformatics in Complex Matrices: Deconvolution Methodologies

While detecting the binary presence of SARS-CoV-2 in a wastewater sample is analytically straightforward using standard polymerase chain reaction assays, determining exactly which specific variants and sublineages comprise that mixed environmental sample is computationally profound. A single sample of aircraft wastewater extracted from a triturator may contain fragmented genetic material shed by hundreds of different passengers, each potentially carrying different viral variants.¹⁶ Furthermore, the nucleic acids extracted from these harsh environmental sources are typically highly fragmented, sparse, and chemically degraded, leading to notoriously low sequencing coverage and shallow read depths.¹⁶

Standard genomic assembly pipelines were designed almost exclusively for clinical samples, such as a nasal swab taken from a single patient, where a single, relatively intact viral lineage dominates the entire biological matrix.¹⁷ When these traditional pipelines are applied to wastewater, they routinely fail. They struggle to differentiate whether a newly observed combination of mutations in the data belongs to a single, novel recombinant virus that has just emerged, or if the algorithm is simply reading an aggregate mixture of mutations shed independently by several distinct, well-known co-circulating strains.¹⁸ To resolve this bioinformatics bottleneck, specialized computational pipelines have been developed to demix environmental data.

The Freyja Pipeline and Lineage Barcoding

The most prominent and widely adopted bioinformatic tool engineered specifically for this purpose is Freyja, currently operating in its second iteration as Freyja 2.¹⁶ Rather than attempting the near-impossible task of assembling full, contiguous viral genomes from billions of highly fragmented wastewater reads, Freyja analyzes the sample at the level of individual, specific mutations.

The core algorithm relies on exploiting the mathematical relationship between the observed frequency of a single nucleotide polymorphism in the sequenced sample and the overall frequency of the specific pathogen lineages that are biologically defined by those exact polymorphisms.¹⁹ To achieve this, Freyja pre-encodes the characteristic sequence of single nucleotide polymorphisms that define every known global viral lineage into a massive library of binarized "lineage barcodes".¹⁹

When a complex wastewater sample is sequenced using targeted tiled amplicon primers, the pipeline generates a comprehensive observed frequency profile for all detected single nucleotide polymorphisms in that specific mixture. Freyja then utilizes a sophisticated constrained optimization mathematical method to demix the sample. It employs a weighted absolute-difference norm algorithm, carefully adjusting the mathematical weights based on the site-specific sequencing depth across the genome, to calculate the exact combination and proportion of theoretical lineage barcodes that best explain the empirical mutational profile observed in the raw data.¹⁶ The algorithm strictly operates under two logical constraints: first, the estimated prevalence of any specific lineage cannot be a negative number, and second, the sum of all predicted lineage proportions within the sample must perfectly equal one hundred percent.¹⁹

This approach allows for highly flexible and remarkably accurate surveillance, demonstrating substantial robustness even when total genomic coverage is incomplete or highly fragmented.¹⁹ Validation studies conducted across dozens of treatment plants in the United States have demonstrated that the wastewater lineage abundances calculated by the Freyja pipeline show strong, statistically significant positive correlations with parallel clinical surveillance data.¹⁸ The pipeline has successfully and accurately tracked the complex succession patterns of major variants, capturing the transitions from Omicron XBB lineages to JN.1, followed by the emergence of KP, XEC, and LP lineages, often providing actionable prevalence data far faster than traditional clinical sequencing networks.¹⁸

Evolutionary Dynamics of Emerging SARS-CoV-2 Variants

The continuous genomic surveillance of international travelers and corresponding wastewater streams has illuminated the complex, non-linear evolutionary pathways of SARS-CoV-2. The virus utilizes a multi-faceted approach to biological adaptation, characterized by both persistent, gradual antigenic drift and sudden, episodic evolutionary leaps known in virology as saltations.²⁰ Antigenic drift involves the gradual, stepwise accumulation of single point mutations that slightly alter the virus's surface proteins over time, slowly eroding the efficacy of pre-existing population immunity. Saltation events, however, represent massive, sudden evolutionary deviations that introduce entirely new viral architectures to the global population.

Mechanisms of Viral Saltation and Persistent Infections

Saltation variants typically present with dozens of novel mutations in their spike proteins and display no known circulating evolutionary intermediate strains in the global genomic databases. It is widely hypothesized that these long-branch variants do not evolve through standard, acute community transmission.²¹ In acute infections, the virus transmits rapidly from host to host, passing through strict transmission bottlenecks that physically restrict the simultaneous accumulation of multiple advantageous mutations.²¹ Instead, saltation events are believed to incubate internally within individuals suffering from chronic, persistent infections, most frequently observed in severely immunocompromised patients.²¹

In these unique hosts, the virus can continuously replicate and mutate over the course of months or even years. The weakened host immune system is capable of applying continuous selective pressure on the virus—forcing it to adapt and mutate to survive—but is ultimately incapable of fully clearing the infection.²¹ When this highly mutated, highly adapted virus eventually transmits back into the general population, it emerges as a radically distinct, fully formed lineage capable of bypassing widespread population immunity.²¹

Recombination Events and Convergent Evolution

While saltation drives the emergence of highly divergent phylogenetic branches, other variants arise through the mechanism of genetic recombination. Recombination occurs when a single human host is simultaneously co-infected by two distinct SARS-CoV-2 lineages. During the process of viral replication within the host cell, the viral polymerase enzyme can physically jump between the two different RNA templates, generating a hybrid genome that incorporates traits from both parent viruses.²²

The XEC variant, heavily monitored in recent surveillance cycles, is a primary example of this phenomenon. It derived from a definitive recombination event between the KP.3.3 and KS.1.1 lineages.²² Detailed phylogenomic surveillance indicates that the exact genetic recombination breakpoint occurred within the spike protein gene, spanning specific nucleotide positions that mark a definitive shift from the KS.1.1 genetic sequence directly to the KP.3.3 sequence.²² XEC harbors key mutations such as Q493E and L455S, which confer specific immunogenic properties and alter its affinity for human cellular receptors.²² However, despite these adaptations, phylodynamic tracking and complex Bayesian Skyline Plot analyses of wastewater and clinical data suggest that XEC possesses low genetic variability and a stably declining population size, indicating that it represents an evolutionary dead-end with limited long-term epidemiological significance.²²

Conversely, variants driven by convergent evolution represent a much more persistent threat. Convergent evolution occurs when entirely disparate viral lineages independently acquire the exact same advantageous mutations under similar global immune selection pressures.²³ The NB.1.8.1 variant represents a significant threat driven by this mechanism. It exhibits recurrent convergent mutations such as Q493E, A435S, and K478I.²⁴ This variant has managed to successfully retain high chemical affinity for human ACE2 receptors while simultaneously demonstrating robust evasion of humoral immunity.²⁴ This optimal evolutionary balance of high receptor engagement and potent antibody escape grants NB.1.8.1 a distinct, measurable growth advantage over older lineages, making it a prime candidate for future global dominance.²⁴

The Genomic and Structural Paradox of Variant BA.3.2

One of the most consequential discoveries in recent genomic biosurveillance is the emergence of the BA.3.2 subvariant, which perfectly illustrates the extremes of viral saltation. First detected in South Africa in late 2024, BA.3.2 descends directly from the BA.3 lineage, an early Omicron subvariant that had essentially ceased global circulation in early 2022.²¹ The sudden, unexpected reappearance of a BA.3 descendant over two years later, bearing fifty-one new mutations relative to its ancestor, strongly supports the hypothesis of an origin from an unmonitored persistent infection lasting over a year.²¹ Phylogenetic analyses trace the root of the BA.3.2 branch firmly to Southern Africa, a region structurally identified as a persistent hotspot for long-branch variant generation, likely due to a high localized prevalence of immunocompromise associated with advanced HIV disease.²¹

From its origin, the variant spread globally, largely tracked through traveler surveillance. The first domestic identification of the strain in the United States occurred in June 2025, successfully intercepted by the Traveler-Based Genomic Surveillance program in a passenger arriving from the Netherlands.²⁶ This environmental and traveler detection preceded the first domestic clinical detection of BA.3.2, which did not occur until January 2026.²⁶ The variant has demonstrated a slow but highly persistent global circulation, detected in over one hundred and thirty-two wastewater samples across twenty-five states in the US, and reaching a prevalence of nearly thirty percent of sequenced cases in Denmark, Germany, and the Netherlands by early 2026.²⁷

BA.3.2 possesses several extreme genomic anomalies that complicate its detection and analysis. Most notably, almost all BA.3.2 sequences harbor a massive, contiguous deletion of approximately eight hundred and seventy base pairs.²¹ This deletion is structurally devastating; it completely removes the Open Reading Frame 7 (encompassing both ORF7a and ORF7b) and Open Reading Frame 8 regions from the viral genome.²¹ Furthermore, because this massive deletion physically eliminates the canonical genetic stop codon of the preceding ORF6 gene, a novel stop codon is forced to generate immediately upstream of the nucleocapsid gene.²¹ In standard, automated bioinformatics assembly pipelines, this massive deletion is frequently misinterpreted as a simple lack of sequencing coverage, resulting in pipelines outputting long stretches of ambiguous characters rather than correctly identifying the structural deletion.²¹

The Virological Trade-off: Evasion versus Fitness

The spike glycoprotein of BA.3.2 exhibits thirty-nine distinct amino acid mutations compared to its BA.3 ancestor.²¹ These profound structural alterations have created a fascinating paradox regarding the variant's virological fitness and epidemic potential.

Extensive pseudovirus infectivity assays reveal that BA.3.2 possesses an unparalleled ability to evade pre-existing human humoral immunity. It is structurally and antigenically distinct from the dominant JN.1 and XBB lineages.²⁴ In tests utilizing human convalescent plasma, BA.3.2 demonstrated an eleven-fold reduction in geometric mean neutralizing titers compared to BA.3, and a massive three to four-fold reduction even when compared to highly evasive contemporary strains like LP.8.1.1.²⁴ Crucially, BA.3.2 exhibits incredibly robust escape from Class 1 and Class 4 monoclonal antibodies.²⁴ These specific classes of antibodies are highly potent, broad-spectrum neutralizing agents that target conserved epitopes on the receptor-binding domain of the virus. While most other emerging variants remain highly susceptible to Class 1 and Class 4 antibodies, specific point mutations present in BA.3.2, particularly the K478N mutation, completely abolish their neutralizing efficacy.²⁴

However, this profound, almost total immune evasion comes at a severe biological cost to the virus's overall fitness. The massive accumulation of mutations in the BA.3.2 spike protein has forced the protein into a predominantly compact, asymmetrical, and highly rigid "closed" structural conformation.²⁰ For SARS-CoV-2 to successfully infect a human host cell, the receptor-binding domain of the spike protein must be able to fluidly toggle into an "up" or "open" conformation to physically bind with the human ACE2 receptor.²⁰ While isolated, detached receptor-binding domain subunits of BA.3.2 demonstrate strong chemical affinity for ACE2 in a vacuum, the rigid, closed geometry of the full, intact spike protein prevents efficient receptor engagement in reality.²⁴

Consequently, despite its ability to completely ignore antibodies, BA.3.2 exhibits disastrously low infectivity and replication fitness in live cell cultures.²⁴ This structural trade-off—maximizing immune evasion at the direct expense of physical receptor binding efficiency—explains the epidemiological behavior of BA.3.2. It clarifies why the variant has maintained a persistent but remarkably low-level global circulation without triggering massive, explosive outbreaks comparable to the historical JN.1 or Omicron waves.²⁰ Virologically, it represents a potential evolutionary dead-end unless it manages to acquire specific compensatory mutations in the future that can stabilize an open spike conformation while simultaneously preserving its formidable antibody resistance.²⁴

Variant Lineage	Evolutionary Origin	Key Genomic Features	Immune Evasion Profile	Infectivity & Receptor Binding
BA.3.2	Saltation from BA.3 (Southern Africa). Assumed chronic infection.	~870 bp deletion (ORF7/8). K478N mutation. 39+ spike mutations.	Profound escape. Near-total resistance to Class 1 and 4 broad-spectrum monoclonal antibodies.	Disastrously low. Rigid, closed spike conformation severely prevents efficient ACE2 engagement.
NB.1.8.1	Evolutionary drift via Convergent evolution.	Q493E, A435S, K478I mutations.	High humoral evasion.	Highly efficient. Maintains excellent ACE2 binding affinity. High potential for global dominance.
XEC	Recombinant hybrid (KP.3.3 and KS.1.1).	L455S, Q493E. Genetic breakpoint in spike gene.	Moderate. Shares traits with both parental lineages.	Limited spread. Structurally viable but actively outcompeted by newer, fitter lineages.
LF.7.9 / XFG	Evolutionary drift.	A475V (LF.7.9), N487D (XFG).	Strong targeted escape from Class 1 and 2 antibodies.	Reduced receptor-binding efficiency. Requires compensatory mutations to optimize future fitness.

Mechanisms of Viral Immune Evasion: Adaptive and Innate

The evolutionary success of SARS-CoV-2 and its continued persistence in the global population relies not only on evading the adaptive immune system—represented by the neutralizing antibodies targeted by the aforementioned spike protein mutations—but also on aggressively and rapidly suppressing the human host's innate immune system.

Innate immunity acts as the body's immediate, first line of defense against viral intruders, utilizing a cascade of interferons to quickly establish an antiviral state in infected and neighboring epithelial cells. Overcoming this initial barrier is absolutely critical for the virus to establish a foothold in the human respiratory tract before the adaptive immune system can even begin to respond.²³ While the vast majority of public and clinical attention is hyper-focused on the structural remodeling of the spike protein, genomic surveillance has revealed a highly effective, convergent evolutionary pathway across Omicron subvariants focused specifically on enhancing the expression of innate immune antagonists.²³

Mutations in other, less publicized regions of the viral genome, specifically regarding Open Reading Frame 6 (Orf6) and the viral nucleocapsid proteins, play devastating roles in this early immune suppression.²³ Upon initial infection, human respiratory cells typically produce Type-I and Type-III interferons. Type-III interferons are particularly crucial in the mucosal tissue of the upper airways and human intestinal epithelial cells, where their primary function is to chemically hinder the viral life cycle and prevent replication.³⁰

However, advanced SARS-CoV-2 variants actively induce a dysregulation of this critical response. Research indicates that the virus actively suppresses the early production of these interferons, creating a vital temporal window that allows for massive, unchecked viral replication in the airways.²³ The primary mechanism for this sophisticated suppression involves the viral Orf6 protein. Once produced within the host cell, Orf6 directly interacts with the Nup98-Rae1 complex, a critical structural component of the host cell's nuclear pore.³⁰ By physically binding to the nuclear pore complex, Orf6 obstructs the nuclear translocation of STAT1 and IRF3, which are essential transcription factors required to activate the host's interferon signaling pathways.²³

Without STAT1 and IRF3 successfully entering the cell nucleus, the human cell simply cannot transcribe the genetic instructions necessary to mount an antiviral interferon defense. Advanced Omicron subvariants, particularly those descending from the BA.4, BA.5, and later XBB lineages, show a marked, measurable increase in the cellular expression of these viral innate antagonists compared to early pandemic strains like Alpha or Delta.²³ This enhanced suppression allows the modern virus to achieve a significantly higher viral burden in the upper airways during the very early stages of the infection cycle.

Paradoxically, while the virus aggressively suppresses the early, highly beneficial interferon response required to halt localized transmission, the subsequent, massive viral load eventually triggers a severely delayed, hyper-inflammatory immune response later in the infection. This delayed reaction typically involves elevated levels of circulatory cytokines, including Interleukin-6, Tumor Necrosis Factor-alpha, and other pro-inflammatory markers, which ultimately drives the severe pathology and tissue damage associated with acute COVID-19 disease.²³

Therefore, the true threat profile of any new variant identified at an international airport cannot be assessed solely by its spike protein. It must be evaluated across two parallel evolutionary tracks: the external structural remodeling of the spike protein designed to physically evade adaptive antibodies, and the internal genomic refinement of non-structural proteins designed to silently disable the host's innate cellular alarms.

Concluding Implications for Global Public Health

The integration of voluntary, traveler-based nasal sampling and the continuous, automated sequencing of aircraft wastewater has fundamentally revolutionized the field of global genomic biosurveillance. By strategically shifting the observational focus away from reactive, localized clinical settings and redirecting it toward the proactive, aggregate monitoring of international transit hubs, public health infrastructure has secured a critical temporal advantage against emerging infectious threats. The Centers for Disease Control and Prevention's expansion of the Traveler-Based Genomic Surveillance program to encompass multi-pathogen multiplexing at nine major international airports reflects a permanent, necessary transition toward persistent, biosecurity-focused monitoring.

The data extracted and deconvoluted from these complex programs highlight the astonishing, continuous evolutionary plasticity of SARS-CoV-2. The emergence of highly divergent saltation variants like BA.3.2—born from isolated chronic infections and featuring massive, structurally altering genomic deletions—underscores the inherent unpredictability of viral evolution. While BA.3.2 currently suffers from rigid structural constraints that severely limit its infectivity, its unprecedented ability to completely evade broad-spectrum Class 1 and Class 4 neutralizing antibodies serves as a stark warning of the virus's adaptive ceiling. Conversely, the rapid rise of variants like NB.1.8.1, which have successfully balanced robust receptor affinity with advanced immune escape through targeted convergent mutation, demonstrates the immediate, ongoing risk of new dominant waves capable of sweeping the globe.

To maintain operational readiness and protect public health, continuous financial and scientific investment in advanced bioinformatics platforms like Freyja 2 is required to accurately decipher the increasingly complex virological data recovered from harsh environmental mixtures. Ultimately, the systematic, border-based sequencing of the highly mobile global traveler population and their associated environmental effluent remains the most robust, unbiased defense mechanism available. It is the only system capable of consistently tracking rapid pathogen evolution, informing the timely reformulation of global vaccines, and providing the critical lead time necessary to mitigate future outbreaks before they take root and multiply in local communities.

Works cited

1. CDC Traveler-based Genomic Surveillance Program Expands to Miami and Chicago, accessed March 24, 2026, https://biosecurity.ginkgo.bio/resources/blog/cdc-traveler-based-genomic-surveillance-program-expands-to-miami-and-chicago

2. Early Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Variants Using Traveler-based Genomic Surveillance at 4, accessed March 24, 2026, https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac461/49125305/ciac461.pdf

3. CDC Traveler-Based Genomic Surveillance Program Tops One Million Participants, Giving Clinical Labs Earlier Warning on Emerging Variants - Dark Daily, accessed March 24, 2026, https://www.darkdaily.com/2026/02/09/cdc-traveler-based-genomic-surveillance-program-tops-one-million-participants-giving-clinical-labs-earlier-warning-on-emerging-variants/

4. CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago - PR Newswire, accessed March 24, 2026, https://www.prnewswire.com/news-releases/cdc-traveler-based-genomic-surveillance-program-to-expand-to-two-new-us-international-airports-in-miami-and-chicago-302085869.html

5. 1 Million Air Travelers Participate in Biosurveillance Program - Vax-Before-Travel, accessed March 24, 2026, https://www.vax-before-travel.com/1-million-air-travelers-participate-biosurveillance-program-2026-01-31

6. CDC Biosurveillance Program Surpasses One Million Air Travelers - TravelPulse, accessed March 24, 2026, https://www.travelpulse.com/news/airlines-airports/cdc-biosurveillance-program-surpasses-one-million-air-travelers

7. US expands testing of international air travellers to cover 30 respiratory viruses | The BMJ, accessed March 24, 2026, https://www.bmj.com/content/383/bmj.p2630

8. About Traveler-Based Genomic Surveillance - CDC, accessed March 24, 2026, https://www.cdc.gov/traveler-genomic-surveillance/about/index.html

9. Wastewater-based SARS-CoV-2 airport surveillance: key trends at the Cape Town International Airport | Journal of Water and Health | IWA Publishing, accessed March 24, 2026, https://iwaponline.com/jwh/article/21/3/402/93859/Wastewater-based-SARS-CoV-2-airport-surveillance

10. Scaling of SARS-CoV-2 RNA in Settled Solids from Multiple Wastewater Treatment Plants to Compare Incidence Rates of Laboratory-Confirmed COVID-19 in Their Sewersheds | Environmental Science & Technology Letters - ACS Publications, accessed March 24, 2026, https://pubs.acs.org/doi/10.1021/acs.estlett.1c00184

11. How Airplane Wastewater Could Help Track the Next COVID Variant, accessed March 24, 2026, https://www.safetyinmotion.aero/news-events/airplane-wastewater-helps-track-covid-variants

12. (PDF) WASTEWATER SURVEILLANCE OF SARS-CoV-2 FROM THE AIRCRAFT AND WASTEWATER TREATMENT PLANTS AT DOMESTIC AND INTERNATIONAL AIRPORTS, THAILAND - ResearchGate, accessed March 24, 2026, https://www.researchgate.net/publication/387147028_WASTEWATER_SURVEILLANCE_OF_SARS-CoV-2_FROM_THE_AIRCRAFT_AND_WASTEWATER_TREATMENT_PLANTS_AT_DOMESTIC_AND_INTERNATIONAL_AIRPORTS_THAILAND

13. Monitoring multi-pathogens and SARS-CoV-2 variants in aircraft and airport wastewater, accessed March 24, 2026, https://www.medrxiv.org/content/10.1101/2024.05.11.24307221v1.full-text

14. Quantifying the relationship between SARS-CoV-2 wastewater concentrations and building-level COVID-19 prevalence at an isolation residence using a passive sampling approach - PMC, accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9016645/

15. Detection of SARS-CoV-2 RNA in wastewater and comparison to COVID-19 cases in two sewersheds, North Carolina, USA - PMC, accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9639408/

16. Real-time, multi-pathogen wastewater genomic surveillance with Freyja 2 | medRxiv, accessed March 24, 2026, https://www.medrxiv.org/content/10.1101/2025.07.26.25332245v1.full-text

17. Evaluation of sampling methods for genomic surveillance of SARS-CoV-2 variants in aircraft wastewater: advancing global early-warning systems for future pandemics - Frontiers, accessed March 24, 2026, https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1717424/full

18. Nationwide wastewater sequencing surveillance of SARS-CoV-2 lineages - PeerJ, accessed March 24, 2026, https://peerj.com/articles/20941.pdf

19. Real-time, multi-pathogen wastewater genomic surveillance with Freyja 2 - PMC, accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12330420/

20. Functional and Structural Basis of Omicron BA.3.2.1 Spike | bioRxiv, accessed March 24, 2026, https://www.biorxiv.org/content/10.64898/2026.02.02.702852v1.full-text

21. Evolution and Viral Properties of the SARS-CoV-2 BA.3.2 Subvariant ..., accessed March 24, 2026, https://www.medrxiv.org/content/10.1101/2025.10.28.25338622v1.full-text

22. SARS-CoV-2 XEC: A Genome-Based Survey - MDPI, accessed March 24, 2026, https://www.mdpi.com/2076-2607/13/2/253

23. The Omicron Variant Enhances Innate Immune Evasion - Contagion Live, accessed March 24, 2026, https://www.contagionlive.com/view/the-omicron-variant-enhances-innate-immune-evasion

24. Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA ..., accessed March 24, 2026, https://www.biorxiv.org/content/10.1101/2025.04.30.651462v1.full-text

25. Evolution and Viral Properties of the SARS-CoV-2 BA.3.2 Subvariant - ResearchGate, accessed March 24, 2026, https://www.researchgate.net/publication/397051285_Evolution_and_Viral_Properties_of_the_SARS-CoV-2_BA32_Subvariant

26. Early Detection and Surveillance of the SARS-CoV-2 Variant BA.3.2 — Worldwide, November 2024–February 2026 - CDC, accessed March 24, 2026, https://www.cdc.gov/mmwr/volumes/75/wr/pdfs/mm7510a1-H.pdf

27. New COVID variant with immune escape potential confirmed in US, 22 other countries, accessed March 24, 2026, https://www.cidrap.umn.edu/covid-19/new-covid-variant-immune-escape-potential-confirmed-us-22-other-countries

28. Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1, accessed March 24, 2026, https://www.biorxiv.org/content/10.1101/2025.04.30.651462v1

29. Functional and Structural Basis of Omicron BA.3.2.1 Spike - ResearchGate, accessed March 24, 2026, https://www.researchgate.net/publication/400448546_Functional_and_Structural_Basis_of_Omicron_BA321_Spike

30. A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations - PMC, accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8863680/